Private equity

We support clients with expert analysis to help them make informed decisions and provide strategy and execution support across the entire investment cycle

“Time is the friend of the wonderful company, the enemy of the mediocre.”

— Warren Buffett

What we do.

Private equity investment in the healthcare industry has gained considerable popularity in mature and emerging markets. The pandemic put healthcare systems under enormous pressure, and the level of interest in healthcare has skyrocketed. Investor optimism has made 2021 the industry’s best year on record. During this time, our team has been actively supporting the funds with due diligence of companies across a range of attractive healthcare sub-sectors.  

Now, it’s a turbulent and far more challenging time in private markets. Russia’s war in Ukraine and inflation have halted the dynamic. Portfolios are fuller, and fundraising and deal-making have been suspended. In the longer term, the healthcare sector will continue to generate investment opportunities, supported by long-term demographic trends and fundamentals. Healthcare innovation is accelerating fast. R&D and tech companies will deliver new products and solutions to address the unmet demands ensuring long-term sector growth.

Before the deal.

We know how critical it is to fully understand the risks and complexities associated with any potential investment. We work closely with private equity, venture capital and family offices to identify and effectively evaluate investment opportunities. Our clients involve us before a transaction to perform pre-investment due diligence and develop a realistic understanding of value creation.

Our track record is built on a foundation that we have rigorously refined during our work on over 50 due diligence analyses of companies in Biotechnology (e.g., start-ups, CDMOs), Medical Devices & Supplies (e.g., manufacturers of implants, IVD tests, surgical robots), Healthcare Providers & Services (e.g., telemedicine providers, nursing software providers), Pharmaceuticals (e.g. manufacturers, wholesalers, online retailers) and other adjacent industries and sectors. Our work is driven through collaboration with advisors with a deep understanding of the investor requirements and investment lifecycle.

After the deal.

We develop strategies to fuel business growth, increase operational efficiencies, and shape organisational structure. The moment a deal closes, we help clients execute targeted plans of action to capture near-term opportunities or support key aspects of a company’s transformation mid-term.

We provide coherent leadership to strengthen the collaboration of board members to ensure efficient resource allocation and discussion of challenges and opportunities. Our proven approach for creating cross-functional collaboration helps CEOs unleash organisational alignment across all operational areas, including sales, access and product development, etc. Our clients appreciate the experience, dynamism and dedication we bring to drive bottom-line results and the creation of greater value.

Case studies